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Abstract 
Background: Nasopharyngeal carcinoma (NPC) is a major head and neck cancer with high occurrence in Southeast 
Asia and southern China. We aimed to identify autoantibodies that may contribute to early detection of NPC.
Methods: We used serological proteome analysis to identify candidate autoantibodies against tumor‑associated 
antigens. Levels of autoantibodies and Epstein–Barr virus capsid antigen‑IgA (VCA‑IgA) were measured by ELISA in 
129 patients with NPC and 100 normal controls. We employed receiver operating characteristics to calculate diagnos‑
tic accuracy.
Results: Sera from patients with NPC yielded multiple spots, two of which were identified as PRDX2 and PRDX3. 
Levels of serum autoantibodies against PRDX2 and PRDX3 were significantly higher for patients with NPC than for 
normal controls (P < 0.01), respectively. Combined detection of autoantibodies against PRDX2 and PRDX3 and VCA‑
IgA provided a high diagnostic accuracy in NPC (an area under the curve (AUC) of 0.811 (95% CI 0.753–0.869), 66.7% 
sensitivity, and 95.0% specificity). This combination maintained diagnostic performance for early NPC with AUC value 
of 0.754 (95% CI 0.652–0.857), 50.0% sensitivity, and 95.0% specificity.
Conclusions: This study reports autoantibodies against PRDX2 and PRDX3 identified by a proteomic approach in 
sera from NPC patients. Our findings suggest that autoantibodies against PRDX2 and PRDX3 may serve as supplemen‑
tary biomarkers to VCA‑IgA for the screening and diagnosis of NPC.
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Background
Nasopharyngeal carcinoma (NPC) is one of the most 
common tumors in the head and neck, with 86,500 new 
cases in 2012 worldwide [1]. The geographical distribu-
tion of NPC is very unique, with 71% of all new cases in 
east, southeast Asia and the remainder in south-central 
Asia, and north and east Africa [1]. Besides difference in 
geographical condition, some ethnic groups including 
the Nagas in northern India, the Bidayuh in Borneo, and 
Inuits in the Artic, also appear to have a predisposition 
for NPC [2]. In the aspect of the demographics, men are 
two to three times more likely to suffer from NPC than 
are women, and peak incidence is between the ages of 50 
and 60 years [1]. The overall survival in early-stage NPC 
patients is obviously longer than that in patients with 
advanced stage [3–5]. The 5 years’ survival rate for stage 
IVA, B and C patients were only 67, 68 and 18%, respec-
tively, while it could reach up to 100 and 95% for stage 
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I and II patients after treatment, respectively [5]. More-
over, treatment-related morbidities more frequently 
occur in those patients with advanced disease [3]. How-
ever, due to deep anatomical site and the lack of specific 
symptoms at early stage, 75–90% of patients with NPC 
present with late stage of disease at clinical diagnosis [3, 
6]. Thus, early diagnosis based on biomarker screening 
method may contribute significantly to NPC therapy and 
prognosis.
NPC is closely associated with Epstein–Barr virus 
(EBV), which is present in almost every NPC case, 
regardless of geographic distribution and histologic dif-
ferentiation [7–9]. At present, the attempts for early 
NPC diagnosis mainly depends on various EBV-derived/
related factors. EBV viral capsid antigen immunoglobulin 
A (VCA-IgA) and EBV DNA, the most commonly used 
serum/plasma biomarkers for NPC, have been found to 
be not sensitive and specific enough for early diagnosis 
purpose [10–12]. A recent meta-analysis showed that 
the sensitivity and specificity of VCA-IgA in diagnosis of 
NPC were 83 and 85%, respectively, and they were 75 and 
87% for EBV DNA [12]. Other effective biomarkers for 
improving early NPC detection are thus clearly needed. 
In recent years, autoantibodies against tumor-associated 
antigens (TAAs) as serum biomarkers show potential 
availability for early cancer diagnosis, which could be 
detected prior to the onset of cancer [13–19]. Our pre-
vious studies also indicated that autoantibodies could 
serve as possible biomarkers for early detection of NPC 
[13, 14]. Here, we used a proteomic-based approach and 
identified novel TAAs PRDX2 and PRDX3 that induces 
an antibody response in patients with NPC.
Methods
Study design and participants
Approval for the study from the institutional ethics 
review committee center was obtained, and written 
informed consents were obtained from all patients and 
normal controls.
We included 7 NPC samples and 7 control samples 
in the “discovery” stage of this study (i.e. the serological 
proteome analysis, SERPA), who were consecutively col-
lected from the Cancer Hospital of Shantou University 
Medical College, China, in February 2015. To further 
validate our findings in the SERPA, we performed the 
enzyme-linked immunosorbent assay (ELISA) in the vali-
dation stage using 129 NPC patients and 100 normal con-
trols, which were recruited consecutively in the Cancer 
Hospital of SUMC from July, 2014, to July, 2015 and from 
the healthy staff members of this hospital between April, 
2012, and June, 2014, respectively. The participants’ fea-
tures are summarized in Table  1. NPC was defined and 
biopsy proven as described in our previous study [14]. 
Tumor stage was defined according to the seventh edi-
tion of the UICC/AJCC staging system for NPC [20].
The recruited patients were all newly diagnosed. We 
classified tumors with AJCC stage I  +  II as early-stage 
NPC as reported previously [13]. Details for blood sam-
ple collection, processing and storage of serum sample of 
all participants were described in our previous publica-
tion [13].
Cell line
Human NPC cell line CNE2, obtained from Sun Yat-sen 
University Cancer Center, was cultured in RPMI-1640 
medium plus 10% fetal bovine serum. All cells were incu-
bated at 37 °C under an atmosphere of 5% CO2.
Two‑dimensional polyacrylamide gel electrophoresis 
and Western blotting
To discover novel autoantibodies in NPC patients, we 
followed the approach as described previously [21]. Pro-
tein extracts from cultured cells were diluted with two-
dimensional gel electrophoresis (2-DE) sample buffer 
(8 M urea, 4.0% CHAPS, 0.2% (w/v) Ampholyte, 65 mM 
Table 1 Basic patient demographics
Discovery stage Validation stage
NPC Control NPC Control
Number 7 7 129 100
Gender
 Male 5 5 100 41
 Female 2 2 29 59
Mean age ± SD (years) 59 ± 12 59 ± 10 51 ± 12 51 ± 10
Age range (years) 38–76 40–74 19–76 24–79
T stage
 T1 0 19
 T2 2 46
 T3 3 39
 T4 2 25
N stage
 N0 1 17
 N1 1 50
 N2 5 55
 N3 0 7
M stage
 M0 6 122
 M1 1 7
Overall stage
 I 0 4
 II 0 36
 III 4 55
 IV 3 34
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DTT), actively rehydrated into 11  cm, pH 3–10 nonlin-
ear ReadyStrip™ IPG Strips (Bio-Rad, Hercules, Califor-
nia) by incubating for 15 h at 20 °C in a strip holder, and 
subjected to isoelectric focusing gel electrophoresis (the 
first-dimension gel). We performed the isoelectric focus-
ing in the PROTEAN IEF cell at 250 V for 30 min, 1000 V 
for 30  min, 8000  V for 4  h, and 8000  V for 40,000  V-h. 
After focusing, the IPG strips were incubated for 15 min 
with equilibration solutions (375 mM Tris–HCl (pH 8.8) 
containing 6 M urea, 20% (w/v) glycerol, and 2.0% (w/v) 
SDS) supplemented with 10 mg/ml DTT and 25 mg/ml 
iodoacetamide. The treated gel strips were loaded onto 
the second-dimension gel, after which the gels were 
stained using a Pierce Silver Stain Kit (Thermo, Waltham, 
MA) or transferred onto a Hybond P polyvinylidene fluo-
ride (PVDF) membrane using the iBlot® 2 Dry Blotting 
System (Thermo). After transfer, PVDF membranes were 
blocked with blocking buffer (PBS/0.05% Tween 20 with 
5.0% nonfat dry milk), and then incubated overnight at 
4 °C with diluted sera from NPC patients or normal con-
trols at 1:250 dilution. After washing, membranes were 
incubated with horseradish peroxidase (HRP)-conjugated 
goat anti-human IgG (Santa Cruz Biotechnology, Dallas, 
Texas) at 1:6000 dilution for 1.5 h at room temperature. 
Bound antibodies were detected by luminal reagent.
In‑gel digestion and purification of peptides
Bands were excised from the gels and subjected to in-gel 
tryptic digestion. Briefly, the silver staining bands were 
excised and washed with 10% acetic acid/50% ethanol for 
overnight, and further soaked in water for 20  min. The 
gel slices were cut into 1 × 1 mm pieces after destained 
with 100 mM potassium ferricyanide and 30 mM sodium 
thiosulfate. The gel slabs were washed with water, 25 mM 
ammonium bicarbonate in ethanol/water and acetonitrile, 
respectively. After completely dehydrated, it was dried 
using the SpeedVac. Each sample was further subjected 
to reduction and alkylation as following procedure. DTT 
was added into the sample (final concentration of 5 mM) 
and incubated at RT for 45 min. Iodoacetamide was added 
at a final concentration of 10  mM and incubated at RT 
for 30 min in the dark. After rehydrated, the gel particles 
were incubated with trypsin solution (10 μg/ml in 50 mM 
ammonium bicarbonate) at 37  °C overnight. The in-gel 
digests were extracted and concentrated to complete dry-
ness using the SpeedVac and stored at −20 °C.
Nano‑HPLC–MS/MS analysis and data interpretation
The resulting samples were desalted using a C18 ZipTip 
(Millipore Corporation, Billerica, Massachusetts, USA), 
respectively, prior to Nano-LC–MS/MS analysis. Each 
tryptic digestion was reconstituted in 5 µL of LC buffer 
A (0.1% (v/v) formic acid in water and injected into a 
Nano-LC system (EASY-nLC 1000, Thermo Fisher Sci-
entific, Waltham, MA). The peptides were separated 
by a C18 column (50 μm inner-diameter ×  15 cm) with 
a 60  min HPLC-gradient (linear gradient from 2 to 35% 
HPLC buffer B (0.1% formic acid in acetonitrile) in 
50 min, and then to 90% buffer B in 10 min). The HPLC 
elution was electrosprayed directly into a Q Exactive 
mass spectrometer (Thermo Fisher Scientific, Waltham, 
MA). The mass spectrometric analysis was carried out in 
a data-dependent mode, and the parameters were set as 
followings. The voltage at source was 1.8 kV. For full MS, 
scan range was from 350 to 1750 with the resolution of 
70,000. The 10 most intense peaks with charge state 2 or 
3 were selected for MS2 analysis (higher-energy collision 
dissociation: normalized collision energy of 27%, the reso-
lution of MS2: 17,500 resolution, the dynamic exclusion 
duration for the data-dependant scan: 18  s, the repeat 
count: 2, and the exclusion window: ±1.5 Da). All MS/MS 
spectra were searched against the Uniprot-Human pro-
tein sequence database using the PD search engine (ver-
sion 2.1.0, Thermo Fisher Scientific) with an overall false 
discovery rate (FDR) for peptides of less than 1%. Trypsin 
was specified as digesting enzyme. A maximum of 2 miss-
ing cleavages was allowed. Mass tolerances for precursor 
ions were set at ±10 ppm for precursor ions and ±0.02 Da 
for MS/MS. Oxidation of methionine and acetylation on 
protein N-terminal were fixed as variable modifications. 
Carbamidomethylation on Cys was specified as fixed 
modification. All MS/MS spectra were manually verified.
ELISA for autoantibodies
ELISA for autoantibodies against PRDX2 and PRDX3 
was performed by two researchers (Yi-Wei Xu and Lie-
Hao Lin) as previously described [13, 18]. Briefly, purified 
recombinant antigens, PRDX2 (Sino Biological Inc.) and 
PRDX3 (Abcam, ab168006) were diluted to a final protein 
concentration of 0.1 and 0.3 μg/ml, respectively. 100 μl of 
serum samples and quality control samples (i.e. a pooled 
serum sample collected randomly from 50 patients with 
NPC) were diluted (1/110), added to the plates, as well as 
appropriate control rabbit polyclonal antibodies specific 
for capture proteins (rabbit anti-PRDX2 polyclonal anti-
body, Sino Biological Inc; rabbit anti-PRDX3 polyclonal 
antibody, Sino Biological Inc). Horseradish peroxidase 
(HRP)-conjugated goat anti-human/rabbit IgG (Santa 
Cruz Biotechnology) was added at 1:10,000 dilution.
Quality control for monitoring of the ELISA assay was 
conducted according to our previous study [13, 18].
ELISA for EBV VCA‑IgA
Concentrations of VCA-IgA in all samples were deter-
mined in duplicate by ELISA using commercial kits 
(Berer Bioengineering, Beijing, China). We conducted 
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the experiments according to the manufacturer’s instruc-
tions as previously described [13, 14].
Statistical analysis
We used the Mann–Whitney U test for analyses that 
compared levels of individual autoantibodies in serum 
between NPC patients and normal controls. For diag-
nostic ability of individual autoantibodies and jointly 
biomarker, we plotted receiver operating character-
istic (ROC) analysis to assess optimum cutoff value, 
area under the ROC curve (AUC) with 95% confidence 
interval (CI), sensitivity, and specificity. The optimum 
cutoff value for positive reactivity was determined by 
achieving the maximum sensitivity when the specificity 
was >95%, and by minimizing the distance of the cut-
off value to the top-left corner of the ROC curve. To 
test the diagnostic accuracy when the different mark-
ers were combined, we estimated functions of the com-
bined markers by binary logistic regression, and the 
values of these functions were used as one marker and 
subjected to ROC analysis [22]. We used Chi-squared 
tests or Fisher’s exact tests for comparisons of the clini-
cal relevance of individual and combined tests. All sta-
tistical analyses were performed with SPSS (version 
17.0), or GraphPad Prism software. We considered a p 
value (two sided) of lower than 0.05 to be statistically 
significant.
Results
Identification of autoantibodies by serological proteome 
analysis
Human NPC CNE2 cell proteins were separated by 2-DE, 
and transferred onto PVDF membranes or visualized by 
silver staining (Fig.  1d). The membranes were screened 
individually from 7 NPC patients and from 7 matched 
normal controls to identify the presence of autoanti-
bodies against candidate antigens from CNE2 cells. 
We selected 14 reactive spots in total observed in NPC 
patients for identification using the Nano-HPLC–MS/MS 
(Fig. 1a, b). Meanwhile there were no such reactive spots 
(or spots with weak immunoreactivity) within 7 healthy 
controls (Fig.  1c). We also observed that each selected 
target identified by the Nano-HPLC–MS/MS analysis 
correlated highly to the predicted molecular mass on gel 
from which it was originally excised (Table  2). Among 
these reactive spots, spot numbers 1 and 2, which were 
observed in 2 and 3 of 7 NPC patients, respectively 
(Fig. 1a), were identified as PRDX2 and PRDX3, respec-
tively (Table  2). Both of the autoantibody biomarkers 
were selected to evaluate the diagnostic value for NPC 
with use of a validation cohort.
Validation of autoantibodies against PRDX2 and PRDX3 
for NPC
In the validation stage, the circulating levels of autoanti-
bodies against PRDX2 and PRDX3 on ELISA were signif-
icantly higher in NPC cases, respectively, compared with 
control individuals (Fig. 2, P < 0.01). ROC curve showed 
that the cutoff values of autoantibody against PRDX2 and 
PRDX3 were 0.173 and 0.608, respectively, with sensi-
tivities/specificities of 26.4/96.0, 24.5/95.0%, and AUC 
values of 0.614 (95% CI 0.542–0.686) and 0.600 (95% CI 
0.528–0.673) for discriminating NPC from normal con-
trols (Fig.  3, Table  3). Predictive values and likelihood 
ratios for autoantibodies against PRDX2 and PRDX3 in 
the diagnosis of NPC are also shown in Table 3.
To estimate the diagnostic ability of the combined use 
of the two autoantibody markers, a variable predicted 
probability (p) of being detected as NPC was created 
based on an equation obtained by binary logistic regres-
sion (all NPC vs. all controls): ln (p/(1 − p)) = 6.040 × 
(PRDX2)  +  2.062  × (PRDX3)  −  1.339. The efficacy 
of combination of autoantibodies against PRDX2 and 
PRDX3 is presented in Fig. 3 and Table 3. Use of the com-
bination of autoantibodies against PRDX2 and PRDX3 
provided a sensitivity of 36.4% and a specificity of 95.0%.
Combined detection of autoantibodies and VCA‑IgA 
for NPC
According to the manufacturer’s instructions, the rec-
ommended clinical cutoff value of VCA-IgA was 0.150. 
The sensitivities/specificities of VCA-IgA for all NPC 
and early-stage NPC were 48.8/95.0 and 32.5/95.0%, 
respectively (Table  3). We then examined whether the 
combined detection of VCA-IgA and autoantibody bio-
markers would further improve the diagnostic accu-
racy for NPC. The predicted probability for NPC using 
the combination of two autoantibodies and VCA-IgA 
was calculated by: ln (p/(1  −  p))  =  6.909  × (PRDX2) 
+2.757  × (PRDX3)  +  3.107  × (VCA-IgA)  −  2.414. As 
expected, ROC analysis illustrated that measurement of 
both autoantibody and VCA-IgA increased the diagnos-
tic accuracy for NPC and early-stage NPC, compared 
with the test of the autoantibody or VCA-IgA alone 
(Fig. 4; Table 3).
The correlation of autoantibody assay positivity 
with Clinicpathological parameters
We evaluated the correlation of positive rates of the 
autoantibody assay with clinical variables in NPC 
patients. We did not find a correlation of assay positiv-
ity with any of the clinicpathological parameters of NPC 
patients (Table 4).
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Fig. 1 Representative two‑dimensional protein gel of CNE2 cell lysate proteins with accompanying western blots. a CNE2 cell lysate proteins were 
separated by two‑dimensional PAGE, transferred to PVDF membrane, and then incubated with diluted sera (1:250) from a patient with NPC. b PVDF 
membrane incubated with sera from another patient with NPC. c PVDF membrane incubated with sera from a normal control. PVDF membranes 
were incubated with appropriate secondary antibodies and visualized by chemiluminescence. d Silver stained two‑dimensional gel for total protein 
isolated from the CNE2 NPC cell line
Table 2 List of tumor proteins detected by proteomic identification
Spot no. Proteins Accession no. Molecular weight (kDa) Mascot score Sequence coverage (%)
1 PRDX2 P32119 21.9 45.25 27.27
2 PRDX3 P30048‑2 25.8 61.26 26.05
3 Nucleoside diphosphate kinase A P15531 17.1 319.20 50.66
4 ENO1 P06733 47.1 1101.89 63.36
5 HSPA8 P11142 70.9 166.27 31.42
6 Serine‑threonine kinase receptor‑associated protein Q9Y3F4 38.4 149.54 32.86
7 HSPD1 P10809 61.0 724.87 38.57
8 Serpin B5 P36952 42.1 115.84 19.47
9 L‑lactate dehydrogenase B P07195 36.6 428.81 35.93
10 Gamma‑glutamylcyclotransferase O75223 21.0 40.35 20.74
11 Vimentin P08670 53.6 177.94 45.06
12 NPM1 P06748‑2 29.4 233.66 22.64
13 Isoform 2 of Macrophage‑capping protein P40121‑2 36.8 47.09 10.21
14 Annexin A2 P07355 38.6 208.50 59.59
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Discussion
In this study, we found novel TAAs in NPC cell lines 
(CNE2) and related autoantibodies in serum of patients 
with NPC using SERPA. We then identified autoanti-
bodies against PRDX2 and PRDX3 and verified their 
diagnostic values in 129 patients with NPC and 100 nor-
mal controls. Importantly, combined testing of the two 
autoantibody biomarkers and VCA-IgA in serum could 
provide improved result for diagnosing NPC.
The present study identified 14 tumor autoantibod-
ies that might serve as potential biomarkers for NPC. To 
our knowledge, we first showed the four proteins, Serine-
threonine kinase receptor-associated protein, Gamma-
glutamylcyclotransferase, Serpin B5 and PRDX3, could 
induce autoantibodies among cancer patients. Using a 
validation cohort, we demonstrated that two of these 
biomarkers (autoantibodies against PRDX2 and PRDX3) 
represent novel autoantibody targets for discriminating 
NPC from normal controls. Interestingly, both of PRDX2 
and PRDX3 identified are members of the Peroxiredoxin 
(PRDX) gene family [23]. Peroxiredoxins are a family of 
antioxidant enzymes, which are ubiquitously expressed 
and regulate levels of intracellular H2O2 by catalyzing 
reduction to water [24]. This highly conserved PRDX 
family participates in cellular antioxidant defense, and 
is also associated with cell signaling pathways involv-
ing cell proliferation, differentiation, apoptosis, and 
DNA damage [25, 26]. Several reports have mentioned 






















































Fig. 2 Levels of autoantibodies against PRDX2 and PRDX3. Scatter plots of OD values of autoantibodies against PRDX2 and PRDX3 from NPC sera 
and normal sera. Black horizontal lines are means
PRDX2 autoantibody
PRDX3 autoantibody




PRDX2 autoantibody+ PRDX3 autoantibody
Reference line
a b
Fig. 3 ROC curve analysis of autoantibodies against PRDX2 and PRDX3 for NPC diagnosis. a ROC curve for serum autoantibodies against PRDX2 and 
PRDX3 and their combination for patients with NPC versus normal controls. b ROC curve for serum autoantibodies against PRDX2 and PRDX3 and 
their combination for patients with early NPC versus normal controls. ROC receiver operating characteristic
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PRDXs as tumor-associated antigen inducing autoan-
tibody production in malignant tumor [13, 18, 27–29]. 
Ren et  al. [27] demonstrated that positivity of autoanti-
body against PRDX1 was observed in sera from 9 of 68 
(13.2%) patients with esophagus squamous cell carci-
noma (ESCC), whereas no such activity was detected in 
89 (0%) normal individuals. We previously showed that 
autoantibody against PRDX6 could serve as a potential 
serum biomarker for early detection of NPC and esoph-
ageal cancer [13, 18]. The present study was the first to 
show the presence of autoantibodies against PRDX2 and 
PRDX3 in sera from patients with NPC. We provided 
evidence that autoantibody against PRDX2 and PRDX3 
could detected early-stage NPC (Table 3), showing their 
potential utility in early diagnosis of NPC.
The detection of cancer at early stage would contribute 
to the treatment and prognosis of cancer patients. There 
are evidences that the screening programs for the early 
detection of tumors, such as colorectal, prostate, breast, 
and lung cancer, can reduce mortality [30–32]. Although 
EBV DNA and antibodies against EBV antigens (e.g. 
VCA-IgA) are clinically used for NPC for many years, 
they may be of limited use as general screening test for 
NPC due to low specificity for distinguishing NPC from 
Table 3 Measurement of PRDX2 autoantibody, PRDX3 autoantibody and their combination of VCA-IgA in NPC diagnosis
AUC area under curve, 95% CI 95% exact confidence interval, NPC nasopharyngeal carcinoma, NC normal controls, PPV positive predictive value, NPV negative 
predictive value, PLR positive likelihood ratio, NLR negative likelihood ratio
AUC (95% CI) Sensitivity (%) Specificity (%) PPV (%) NPV (%) PLR NLR
NPC versus NC
 PRDX2 autoantibody 0.614 (0.542–0.686) 26.4 96.0 89.5 50.3 6.60 0.77
 PRDX3 autoantibody 0.600 (0.528–0.673) 24.5 95.0 86.3 49.4 4.90 0.79
 PRDX2 autoantibody + PRDX3 autoantibody 0.632 (0.561–0.703) 36.4 95.0 90.4 53.7 7.28 0.67
 VCA‑IgA 0.719 (0.653–0.785) 48.8 95.0 92.6 59.0 9.76 0.54
 Autoantibody + VCA‑IgA 0.811 (0.753–0.869) 66.7 95.0 94.5 68.9 13.34 0.35
Early‑stage NPC versus NC
 PRDX2 autoantibody 0.642 (0.532–0.753) 27.5 96.0 73.4 76.8 6.88 0.76
 PRDX3 autoantibody 0.646 (0.537–0.755) 25.0 95.0 66.7 76.0 5.00 0.79
 PRDX2 autoantibody + PRDX3 autoantibody 0.664 (0.550–0.779) 40.0 95.0 76.2 79.8 8.00 0.63
 VCA‑IgA 0.638 (0.528–0.747) 32.5 95.0 72.3 77.8 6.50 0.71
 Autoantibody + VCA‑IgA 0.754 (0.652–0.857) 50.0 95.0 80.0 82.6 10.00 0.53
Fig. 4 ROC curve analysis of the combination of autoantibodies against PRDX2 and PRDX3, and VCA‑IgA. a ROC curve for the combination of 
autoantibodies against PRDX2 and PRDX3, and VCA‑IgA for patients with NPC versus normal controls. b ROC curve for the combination of autoanti‑
bodies against PRDX2 and PRDX3, and VCA‑IgA for patients with early NPC versus normal controls. ROC receiver operating characteristic; NPC
Page 8 of 10Lin et al. Clin Proteom  (2017) 14:6 
other EBV-related diseases in endemic regions and high 
false positive rate for primary screening [33–35]. A relia-
ble biomarker-based assay as a supplement to EBV DNA/
VCA-IgA for the early NPC diagnosis is highly desirable. 
In recent years, autoantibodies show promising value of 
clinical application in terms of the early detection of can-
cer [13–19, 36–38]. For example, EarlyCDT-Lung, as a 
potential complementary tool to computed tomography, 
was the first autoantibody-based diagnostic biomarker 
to be performed for the early detection of lung cancer 
in routine clinical practice [36–38]. For a screening tool 
to be useful, the sensitivity and specificity would be as 
high as possible. However, to qualify as a clinically use-
ful marker/marker panel for initial detection of tumor 
disease, a molecular tumor marker/marker panel must 
have better diagnostic performance (i.e. sensitivity and 
specificity) than tumor markers currently used. We here 
measured the combination of autoantibodies against 
PRDX2 and PRDX3 and VCA-IgA in early-stage NPC 
and normal controls resulting in 50.0% sensitivity with a 
robust specificity of 95.0% (Table 3). The combined assay 
comprising VCA-IgA and autoantibodies against PRDX2 
and PRDX3 demonstrated a better diagnostic ability than 
each one tested alone. Thus, the addition of autoanti-
bodies, one kind of simple and cost-effective biomark-
ers, may improve the diagnostic efficacy for NPC. The 
high specificity suggests that this combined detection 
might also be used in assay positive patients to moni-
tor therapy response or alternatively as a tool to detect 
recurrence. On the other hand, the sensitivity of this test 
would be not high enough to be used for screening pur-
poses in general or high risk populations. Thus, we need 
to identify new autoantibody markers [e.g. other poten-
tial autoantibody markers identified in the present study 
(shown in Table 2)] that could enhance the sensitivity of 
our present combined assay.
It is unclear what is the basis for the humoral responses 
to PRDX2 and PRDX3 antigens in NPC. Generally, cancer-
associated autoantibodies target important protein mole-
cules involved in carcinogenesis, which are deemed to be 
overexpressed, mutated, misfolded, or aberrantly modi-
fied in tumor cells [39, 40]. Overexpression of PRDX2 and 
PRDX3 has been reported in many kinds of cancer though 
it’s low or even undetectable in normal tissues [41, 42]. 
However, whether the autoimmune responses to PRDX2 
and PRDX3 in NPC originate from its overexpression or 
other ways remains to be investigated.
Conclusions
To the best of our knowledge, we are the first to identify 
autoantibodies against PRDX2 and PRDX3 by a prot-
eomic approach in sera from NPC patients. Our results 
Table 4 Association of positive rates of PRDX2 autoantibody and PRDX3 autoantibody with NPC patients’ clinicopatho-
logic characteristics
NPC nasopharyngeal carcinoma
Statistical significance was determined by means of Chi-squared test or Fisher’s exact test (*)
n PRDX2 autoantibody PRDX3 autoantibody Combination
Positive (%) χ2 P Positive (%) χ2 P Positive (%) χ2 P
Gender
 Male 100 26 (26.0%) 1.564 0.211 25 (25.0%) 0.009 0.925 34 (34.0%) 1.138 0.286
 Female 29 11 (37.9%) 7 (24.1%) 13 (44.8%)
Age
 ≤50 61 19 (31.1%) 0.344 0.558 16 (26.2%) 0.126 0.723 21 (34.4%) 0.201 0.654
 >50 68 18 (26.5%) 16 (23.5%) 26 (38.2%)
T stage
 T1 + T2 65 16 (24.6%) 1.059 0.303 19 (29.2%) 1.375 0.241 27 (41.5%) 1.474 0.225
 T3 + T4 64 21 (32.8%) 13 (20.3%) 20 (31.3%)
N stage
 N0 + N1 67 20 (29.9%) 0.093 0.760 15 (22.4%) 0.437 0.509 25 (37.3%) 0.047 0.829
 N2 + N3 62 17 (27.4%) 17 (27.4%) 22 (35.5%)
M stage
 M0 122 34 (27.9%) 0.408* 30 (24.6%) 1.000* 44 (36.1%) 0.705*
 M1 7 3 (42.9%) 2 (28.6%) 3 (42.9%)
Overall stage
 I + II (early stage) 40 11 (27.5%) 0.040 0.842 10 (25.0%) 0.001 0.973 16 (40.0%) 0.318 0.573
 III + IV (advanced stage) 89 26 (29.2%) 22 (24.7%) 31 (34.8%)
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reveal that autoantibodies against PRDX2 and PRDX3 
might serve as a potential supplement to VCA-IgA in 
NPC diagnosis. The combined detection of VCA-IgA 
and autoantibodies against PRDX2 and PRDX3 had a 
better diagnostic sensitivity than VCA-IgA tested alone 
(Table  3; Fig.  4) and a robust specificity, indicating that 
this test might make a contribution to the diagnosis and 
screening of NPC patients. However, due to the small 
size of patients with early disease in the present study, we 
need to further address the early diagnostic value of this 
test in a large cohort study. Another limitation is that we 
just included 7 NPC patients with advanced disease in 
the discovery work. We would conduct comparative anal-
ysis of NPC Stage I/II versus Stage III/IV versus control 
to discover early autoantibody biomarkers in the future 
work. What’s more, our observations also suggest that we 
should conduct further study to validate the diagnostic 
ability of other autoantibodies identified in this study. We 
hope to establish and validate an optimized autoantibody 
panel with VCA-IgA in larger, blinded patient cohorts 
obtained from multiple institutions, which could have 
clinical and economical implications for NPC screening.
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